These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30323643)

  • 21. Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects.
    Desai A; Helmick M; Heo N; Moy S; Stanhope S; Goldwater R; Martin N
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0044221. PubMed ID: 34181478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
    Vincent J; Teng R; Pelletier SM; Willavize SA; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):23S-26S. PubMed ID: 9935253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
    Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
    Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study.
    Han S; Choi HY; Kim YH; Choi S; Kim S; Nam JY; Kim B; Song GS; Lim HS; Bae KS
    Gut Liver; 2023 Jan; 17(1):92-99. PubMed ID: 36317518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study.
    Shimizu H; Nishimura Y; Shiide Y; Ueda M; Yokota S; Kato Y; Hirai M
    Clin Pharmacol Drug Dev; 2023 Jan; 12(1):77-84. PubMed ID: 36225132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
    Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
    Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing.
    Kim HS; Choi YK; Oh M; Cho YS; Ghim JL
    Transl Clin Pharmacol; 2024 Jun; 32(2):98-106. PubMed ID: 38974342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
    Freston JW; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
    Vakily M; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.
    Song Y; Wang X; Perlstein I; Wang J; Badawy S; Frost C; LaCreta F
    Clin Ther; 2015 Aug; 37(8):1703-12. PubMed ID: 26188837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
    Sharma S; Pepin X; Cheung J; Zheng L; Wei H; Townsley D; Han D; Majewski M; Ware JA; Mann J; Munugalavadla V; Sheridan L; Patel P; Gupta A; Tomkinson H
    Br J Clin Pharmacol; 2022 Oct; 88(10):4573-4584. PubMed ID: 35466438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.
    Burkhardt O; Stass H; Thuss U; Borner K; Welte T
    Clin Pharmacokinet; 2005; 44(9):969-76. PubMed ID: 16122283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects.
    Disanto AR; Golden G
    Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
    Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
    Eliot L; Butler J; Devane J; Loewen G
    Clin Ther; 2002 Feb; 24(2):260-8. PubMed ID: 11911556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
    Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
    Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.